Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences, Inc. (RNA) EPS (Basic) (2019 - 2025)

Avidity Biosciences' EPS (Basic) history spans 7 years, with the latest figure at -$1.59 for Q4 2025.

  • For Q4 2025, EPS (Basic) fell 96.3% year-over-year to -$1.59; the TTM value through Dec 2025 reached -$4.97, down 71.38%, while the annual FY2025 figure was -$4.97, 71.97% down from the prior year.
  • EPS (Basic) reached -$1.59 in Q4 2025 per RNA's latest filing, down from -$1.27 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.64 in Q1 2021 to a low of -$1.59 in Q4 2025.
  • Average EPS (Basic) over 5 years is -$0.85, with a median of -$0.8 recorded in 2023.
  • The largest YoY upside for EPS (Basic) was 70.09% in 2021 against a maximum downside of 119.35% in 2021.
  • A 5-year view of EPS (Basic) shows it stood at -$0.84 in 2021, then dropped by 5.95% to -$0.89 in 2022, then increased by 10.11% to -$0.8 in 2023, then fell by 1.25% to -$0.81 in 2024, then plummeted by 96.3% to -$1.59 in 2025.
  • Per Business Quant, the three most recent readings for RNA's EPS (Basic) are -$1.59 (Q4 2025), -$1.27 (Q3 2025), and -$1.21 (Q2 2025).